On-Demand Webinar – Targeting the “Undruggable”: Emerging Degrader Modalities for Novel Target Identification and Validation
Speakers
A significant portion of disease-relevant proteins remain “undruggable” by traditional therapeutic approaches, representing a major hurdle in drug discovery. Targeted protein degradation (TPD) is rapidly advancing as a strategy to overcome this challenge, enabling the selective elimination of previously inaccessible proteins.
In this on-demand webinar, experts from Clarivate, Nurix Therapeutics, Triana, and Monte Rosa Therapeutics explore how a growing array of degrader modalities, including heterobifunctional degraders, molecular glues, antibody-based degraders, and lysosome-targeting agents are transforming discovery pipelines in oncology, neurology, and autoimmune disease.
Watch to learn how to:
- Identify and validate degrader targets in complex disease contexts.
- Understand biological pathways and mechanisms that influence efficacy and safety.
- Evaluate early safety signals and preclinical data to reduce risk and inform go/no go decisions.
- Monitor the competitive landscape and emerging trends in targeted protein degradation research.
With access to integrated, up-to-date intelligence, researchers can stay informed, anticipate safety risks, and make confident, data-driven decisions in this dynamic and promising field.
